Immuneering (IMRX) Expected to Announce Quarterly Earnings on Friday

Immuneering (NASDAQ:IMRX) is expected to announce its earnings results before the market opens on Friday, March 7th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter.

Immuneering Stock Up 1.4 %

IMRX opened at $1.50 on Thursday. Immuneering has a 52 week low of $1.00 and a 52 week high of $6.78. The business has a fifty day simple moving average of $1.94 and a 200-day simple moving average of $1.95. The firm has a market cap of $46.58 million, a P/E ratio of -0.76 and a beta of -0.36.

Wall Street Analyst Weigh In

IMRX has been the topic of several analyst reports. Morgan Stanley cut Immuneering from an “equal weight” rating to an “underweight” rating in a research note on Friday, December 13th. Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price objective on shares of Immuneering in a research note on Thursday, February 6th. Finally, Chardan Capital reiterated a “buy” rating and issued a $13.00 price objective on shares of Immuneering in a research note on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Immuneering currently has a consensus rating of “Hold” and a consensus price target of $9.00.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.